{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:52:40Z","timestamp":1789617160723,"version":"build-2803163510"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T00:00:00Z","timestamp":1670025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T00:00:00Z","timestamp":1670025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"US NIH NCI","award":["R44CA199767"],"award-info":[{"award-number":["R44CA199767"]}]},{"name":"NCI","award":["R01CA197792"],"award-info":[{"award-number":["R01CA197792"]}]},{"name":"NCI","award":["R21CA234701"],"award-info":[{"award-number":["R21CA234701"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s00277-022-05056-7","type":"journal-article","created":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T02:02:23Z","timestamp":1670032943000},"page":"369-383","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Phase I study of opaganib, an oral sphingosine kinase 2-specific inhibitor, in relapsed and\/or refractory multiple myeloma"],"prefix":"10.1007","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6678-8732","authenticated-orcid":false,"given":"Yubin","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasupathi","family":"Sundaramoorthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Gasparetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Feinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengjun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwynn","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Sellars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anderson","family":"Garrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha A.","family":"Tuchman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandi N.","family":"Reeves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiguo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Besim","family":"Ogretmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Maines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vered Katz","family":"Ben-Yair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Plasse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,3]]},"reference":[{"key":"5056_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"R Siegel","year":"2021","unstructured":"Siegel R, Miller K, Fuchs H (2021) Cancer statistics, 2021. CA Cancer J Clin 71:7\u201333","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"5056_CR2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.6004\/jnccn.2022.0002","volume":"20","author":"NS Callander","year":"2022","unstructured":"Callander NS, Baljevic M, Adekola K, Anderson LD, Campagnaro E, Castillo JJ, Costello C, Devarakonda S, Elsedawy N, Faiman M et al (2022) NCCN Guidelines\u00ae Insights: Multiple Myeloma, Version 3.2022. J Natl Compr Canc Netw 20(1):8\u201319","journal-title":"J Natl Compr Canc Netw"},{"key":"5056_CR3","doi-asserted-by":"crossref","unstructured":"Feinberg D, Paul B, Kang Y (2019) The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma. Cellular Immunol 345:103964","DOI":"10.1016\/j.cellimm.2019.103964"},{"issue":"10301","key":"5056_CR4","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","volume":"398","author":"SZ Usmani","year":"2021","unstructured":"Usmani SZ, Garfall AL, van de Donk N, Nahi H, San-Miguel JF, Oriol A, Rosinol L, Chari A, Bhutani M, Karlin L et al (2021) Teclistamab, a B-cell maturation antigen \u00d7 CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet 398(10301):665\u2013674","journal-title":"Lancet"},{"issue":"1","key":"5056_CR5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13045-020-00962-7","volume":"13","author":"B Yu","year":"2020","unstructured":"Yu B, Jiang T, Liu D (2020) BCMA-targeted immunotherapy for multiple myeloma. J Hematol Oncol 13(1):125","journal-title":"J Hematol Oncol"},{"issue":"6","key":"5056_CR6","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk N, Nahi H, San-Miguel JF, Oriol A, Nooka AK, Martin T, Rosinol L, Chari A et al (2022) Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med 387(6):495\u2013505","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"5056_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1182\/blood-2020-134538","volume":"136","author":"A Perrot","year":"2020","unstructured":"Perrot A, Lauwers-Cances V, Cazaubiel T, Facon T, Caillot D, Clement-Filliatre L, Macro M, Decaux O, Belhadj K, Mohty M et al (2020) Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: long-term follow-up analysis of the IFM 2009 Trial. Blood 136(Supplement 1):39\u201339","journal-title":"Blood"},{"issue":"10192","key":"5056_CR8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","volume":"394","author":"P Moreau","year":"2019","unstructured":"Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, B\u00e9n\u00e9 MC, Broijl A, Caillon H, Caillot D et al (2019) Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet 394(10192):29\u201338","journal-title":"Lancet"},{"key":"5056_CR9","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/bs.acr.2018.04.015","volume":"140","author":"CS Lewis","year":"2018","unstructured":"Lewis CS, Voelkel-Johnson C, Smith CD (2018) Targeting sphingosine kinases for the treatment of cancer. Adv Cancer Res 140:295\u2013325","journal-title":"Adv Cancer Res"},{"key":"5056_CR10","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/0-306-48158-8_14","volume":"115","author":"DK Perry","year":"2003","unstructured":"Perry DK, Kolesnick RN (2003) Ceramide and sphingosine 1-phosphate in anti-cancer therapies. Cancer Treat Res 115:345\u2013354","journal-title":"Cancer Treat Res"},{"issue":"29","key":"5056_CR11","doi-asserted-by":"publisher","first-page":"25851","DOI":"10.1074\/jbc.R200007200","volume":"277","author":"S Spiegel","year":"2002","unstructured":"Spiegel S, Milstien S (2002) Sphingosine 1-phosphate, a key cell signaling molecule. J Biol Chem 277(29):25851\u201325854","journal-title":"J Biol Chem"},{"key":"5056_CR12","doi-asserted-by":"crossref","unstructured":"Gupta P, Taiyab A, Hussain A, Alajmi MF, Islam A, Hassan MI (2021) Targeting the sphingosine kinase\/sphingosine-1-phosphate signaling axis in drug discovery for cancer therapy. Cancers (Basel) 13(8):1898","DOI":"10.3390\/cancers13081898"},{"key":"5056_CR13","doi-asserted-by":"publisher","first-page":"4806541","DOI":"10.1155\/2017\/4806541","volume":"2017","author":"NC Hait","year":"2017","unstructured":"Hait NC, Maiti A (2017) The role of sphingosine-1-phosphate and ceramide-1-phosphate in inflammation and cancer. Mediators Inflamm 2017:4806541","journal-title":"Mediators Inflamm"},{"issue":"1","key":"5056_CR14","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nrc.2017.96","volume":"18","author":"B Ogretmen","year":"2018","unstructured":"Ogretmen B (2018) Sphingolipid metabolism in cancer signalling and therapy. Nat Rev Cancer 18(1):33\u201350","journal-title":"Nat Rev Cancer"},{"issue":"37","key":"5056_CR15","doi-asserted-by":"publisher","first-page":"5897","DOI":"10.1038\/sj.onc.1206702","volume":"22","author":"R Kolesnick","year":"2003","unstructured":"Kolesnick R, Fuks Z (2003) Radiation and ceramide-induced apoptosis. Oncogene 22(37):5897\u20135906","journal-title":"Oncogene"},{"issue":"9","key":"5056_CR16","doi-asserted-by":"publisher","first-page":"780","DOI":"10.2174\/187152011797655113","volume":"11","author":"T Pl","year":"2011","unstructured":"Pl T, Wang HG (2011) Editorial [hot topic: therapeutic targeting of the sphingolipid \u201cbiostat\u201d in hematologic malignancies (guest editors: Thomas p. Loughran and Hong-gang wang)]. Anticancer Agents Med Chem 11(9):780\u2013781","journal-title":"Anticancer Agents Med Chem"},{"issue":"6","key":"5056_CR17","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.biochi.2010.02.014","volume":"92","author":"WI Leong","year":"2010","unstructured":"Leong WI, Saba JD (2010) S1P metabolism in cancer and other pathological conditions. Biochimie 92(6):716\u2013723","journal-title":"Biochimie"},{"key":"5056_CR18","doi-asserted-by":"crossref","unstructured":"Snider AJ, Alexa Orr Gandy K, Obeid LM (2010) Sphingosine kinase: role in regulation of bioactive sphingolipid mediators in inflammation. Biochimie 92(6):707\u2013715","DOI":"10.1016\/j.biochi.2010.02.008"},{"issue":"3\u20134","key":"5056_CR19","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s10555-011-9304-1","volume":"30","author":"H Furuya","year":"2011","unstructured":"Furuya H, Shimizu Y, Kawamori T (2011) Sphingolipids in cancer. Cancer Metastasis Rev 30(3\u20134):567\u2013576","journal-title":"Cancer Metastasis Rev"},{"key":"5056_CR20","doi-asserted-by":"crossref","unstructured":"Santos CR, Schulze A (2012) Lipid metabolism in cancer. FEBS J 279(15):2610\u20132623","DOI":"10.1111\/j.1742-4658.2012.08644.x"},{"issue":"9","key":"5056_CR21","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1093\/intimm\/dxz037","volume":"31","author":"H Obinata","year":"2019","unstructured":"Obinata H, Hla T (2019) Sphingosine 1-phosphate and inflammation. Int Immunol 31(9):617\u2013625","journal-title":"Int Immunol"},{"issue":"12","key":"5056_CR22","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1182\/blood-2014-03-559385","volume":"124","author":"JK Venkata","year":"2014","unstructured":"Venkata JK, An N, Stuart R, Costa LJ, Cai H, Coker W, Song JH, Gibbs K, Matson T, Garrett-Mayer E et al (2014) Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma. Blood 124(12):1915\u20131925","journal-title":"Blood"},{"issue":"1","key":"5056_CR23","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1124\/jpet.109.163444","volume":"333","author":"KJ French","year":"2010","unstructured":"French KJ, Zhuang Y, Maines LW, Gao P, Wang W, Beljanski V, Upson JJ, Green CL, Keller SN, Smith CD (2010) Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2. J Pharmacol Exp Ther 333(1):129\u2013139","journal-title":"J Pharmacol Exp Ther"},{"key":"5056_CR24","doi-asserted-by":"crossref","unstructured":"Sundaramoorthy P, Gasparetto C, Kang Y (2018) The combination of a sphingosine kinase 2 inhibitor (ABC294640) and a Bcl-2 inhibitor (ABT-199) displays synergistic anti-myeloma effects in myeloma cells without a t(11;14) translocation. Cancer Med 7(7):3257\u20133268","DOI":"10.1002\/cam4.1543"},{"issue":"8","key":"5056_CR25","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Blade J, Mateos MV et al (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17(8):e328\u2013e346","journal-title":"Lancet Oncol"},{"issue":"1","key":"5056_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/leu.2008.291","volume":"23","author":"RA Kyle","year":"2009","unstructured":"Kyle RA, Rajkumar SV (2009) Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 23(1):3\u20139","journal-title":"Leukemia"},{"issue":"16","key":"5056_CR27","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1158\/1078-0432.CCR-16-2363","volume":"23","author":"CD Britten","year":"2017","unstructured":"Britten CD, Garrett-Mayer E, Chin SH, Shirai K, Ogretmen B, Bentz TA, Brisendine A, Anderton K, Cusack SL, Maines LW et al (2017) A phase i study of ABC294640, a first-in-class sphingosine kinase-2 inhibitor, in patients with advanced solid tumors. Clin Cancer Res 23(16):4642\u20134650","journal-title":"Clin Cancer Res"},{"issue":"10","key":"5056_CR28","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1194\/jlr.D008532","volume":"51","author":"SM Hammad","year":"2010","unstructured":"Hammad SM, Pierce JS, Soodavar F, Smith KJ, Al Gadban MM, Rembiesa B, Klein RL, Hannun YA, Bielawski J, Bielawska A (2010) Blood sphingolipidomics in healthy humans: impact of sample collection methodology. J Lipid Res 51(10):3074\u20133087","journal-title":"J Lipid Res"},{"issue":"13","key":"5056_CR29","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1002\/sim.4054","volume":"30","author":"T Daimon","year":"2011","unstructured":"Daimon T, Zohar S, O\u2019Quigley J (2011) Posterior maximization and averaging for Bayesian working model choice in the continual reassessment method. Stat Med 30(13):1563\u20131573","journal-title":"Stat Med"},{"issue":"495","key":"5056_CR30","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1198\/jasa.2011.ap09476","volume":"106","author":"Y Yuan","year":"2011","unstructured":"Yuan Y, Yin G (2011) Robust EM continual reassessment method in oncology dose finding. J Am Stat Assoc 106(495):818\u2013831","journal-title":"J Am Stat Assoc"},{"key":"5056_CR31","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1198\/jasa.2009.ap08425","volume":"104","author":"G Yin","year":"2009","unstructured":"Yin G, Yuan Y (2009) Bayesian model averaging continual reassessment method in phase I clinical trial. J Am Stat Assoc 104:954\u2013968","journal-title":"J Am Stat Assoc"},{"issue":"7","key":"5056_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0041834","volume":"7","author":"Q Liu","year":"2012","unstructured":"Liu Q, Rehman H, Shi Y, Krishnasamy Y, Lemasters JJ, Smith CD, Zhong Z (2012) Inhibition of sphingosine kinase-2 suppresses inflammation and attenuates graft injury after liver transplantation in rats. PLoS ONE 7(7):e41834","journal-title":"PLoS ONE"},{"issue":"2","key":"5056_CR33","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s10787-010-0060-6","volume":"19","author":"LR Fitzpatrick","year":"2011","unstructured":"Fitzpatrick LR, Green C, Frauenhoffer EE, French KJ, Zhuang Y, Maines LW, Upson JJ, Paul E, Donahue H, Mosher TJ et al (2011) Attenuation of arthritis in rodents by a novel orally-available inhibitor of sphingosine kinase. Inflammopharmacol 19(2):75\u201387","journal-title":"Inflammopharmacol"},{"issue":"2","key":"5056_CR34","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s10787-010-0032-x","volume":"18","author":"LW Maines","year":"2010","unstructured":"Maines LW, Fitzpatrick LR, Green CL, Zhuang Y, Smith CD (2010) Efficacy of a novel sphingosine kinase inhibitor in experimental Crohn\u2019s disease. Inflammopharmacol 18(2):73\u201385","journal-title":"Inflammopharmacol"},{"issue":"13","key":"5056_CR35","doi-asserted-by":"publisher","first-page":"e106272","DOI":"10.15252\/embj.2020106272","volume":"40","author":"G Pei","year":"2021","unstructured":"Pei G, Zyla J, He L, Moura-Alves P, Steinle H, Saikali P, Lozza L, Nieuwenhuizen N, Weiner J, Mollenkopf HJ et al (2021) Cellular stress promotes NOD1\/2-dependent inflammation via the endogenous metabolite sphingosine-1-phosphate. Embo j 40(13):e106272","journal-title":"Embo j"},{"issue":"3","key":"5056_CR36","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1042\/EBC20190091","volume":"64","author":"A Gomez-Larrauri","year":"2020","unstructured":"Gomez-Larrauri A, Presa N, Dominguez-Herrera A, Ouro A, Trueba M, Gomez-Mu\u00f1oz A (2020) Role of bioactive sphingolipids in physiology and pathology. Essays Biochem 64(3):579\u2013589","journal-title":"Essays Biochem"},{"issue":"3","key":"5056_CR37","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nrm.2017.107","volume":"19","author":"YA Hannun","year":"2018","unstructured":"Hannun YA, Obeid LM (2018) Sphingolipids and their metabolism in physiology and disease. Nat Rev Mol Cell Biol 19(3):175\u2013191","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6585","key":"5056_CR38","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/381800a0","volume":"381","author":"O Cuvillier","year":"1996","unstructured":"Cuvillier O, Pirianov G, Kleuser B, Vanek PG, Coso OA, Gutkind S, Spiegel S (1996) Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature 381(6585):800\u2013803","journal-title":"Nature"},{"issue":"1\u20134","key":"5056_CR39","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0090-6980(01)00108-3","volume":"64","author":"A Olivera","year":"2001","unstructured":"Olivera A, Spiegel S (2001) Sphingosine kinase: a mediator of vital cellular functions. Prostaglandins 64(1\u20134):123\u2013134","journal-title":"Prostaglandins"},{"issue":"1","key":"5056_CR40","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.tem.2008.09.004","volume":"20","author":"LA Cowart","year":"2009","unstructured":"Cowart LA (2009) Sphingolipids: players in the pathology of metabolic disease. Trends Endocrinol Metab 20(1):34\u201342","journal-title":"Trends Endocrinol Metab"},{"key":"5056_CR41","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/978-1-4020-8831-5_16","volume":"49","author":"SA Saddoughi","year":"2008","unstructured":"Saddoughi SA, Song P, Ogretmen B (2008) Roles of bioactive sphingolipids in cancer biology and therapeutics. Subcell Biochem 49:413\u2013440","journal-title":"Subcell Biochem"},{"issue":"2\u20133","key":"5056_CR42","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S1388-1981(02)00336-0","volume":"1585","author":"O Cuvillier","year":"2002","unstructured":"Cuvillier O (2002) Sphingosine in apoptosis signaling. Biochim Biophys Acta 1585(2\u20133):153\u2013162","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"5056_CR43","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.cct.2010.11.006","volume":"32","author":"RW Leung","year":"2011","unstructured":"Leung RW, Alison JA, McKeough ZJ, Peters MJ (2011) A study design to investigate the effect of short-form Sun-style Tai Chi in improving functional exercise capacity, physical performance, balance and health related quality of life in people with chronic obstructive pulmonary disease (COPD). Contemp Clin Trials 32(2):267\u2013272","journal-title":"Contemp Clin Trials"},{"issue":"28","key":"5056_CR44","doi-asserted-by":"publisher","first-page":"5580","DOI":"10.1038\/s41388-019-0833-3","volume":"38","author":"CF Lee","year":"2019","unstructured":"Lee CF, Dang A, Hernandez E, Pong RC, Chen B, Sonavane R, Raj G, Kapur P, Lin HY, Wu SR et al (2019) Activation of sphingosine kinase by lipopolysaccharide promotes prostate cancer cell invasion and metastasis via SphK1\/S1PR4\/matriptase. Oncogene 38(28):5580\u20135598","journal-title":"Oncogene"},{"issue":"7","key":"5056_CR45","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1158\/0008-5472.CAN-17-1423","volume":"78","author":"M Nagahashi","year":"2018","unstructured":"Nagahashi M, Yamada A, Katsuta E, Aoyagi T, Huang WC, Terracina KP, Hait NC, Allegood JC, Tsuchida J, Yuza K et al (2018) Targeting the SphK1\/S1P\/S1PR1 axis that links obesity, chronic inflammation, and breast cancer metastasis. Cancer Res 78(7):1713\u20131725","journal-title":"Cancer Res"},{"issue":"20","key":"5056_CR46","doi-asserted-by":"publisher","first-page":"8635","DOI":"10.1158\/0008-5472.CAN-08-0917","volume":"68","author":"I Ader","year":"2008","unstructured":"Ader I, Brizuela L, Bouquerel P, Malavaud B, Cuvillier O (2008) Sphingosine kinase 1: a new modulator of hypoxia inducible factor 1alpha during hypoxia in human cancer cells. Cancer Res 68(20):8635\u20138642","journal-title":"Cancer Res"},{"issue":"3\u20134","key":"5056_CR47","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.prostaglandins.2006.03.001","volume":"79","author":"M Ahmad","year":"2006","unstructured":"Ahmad M, Long JS, Pyne NJ, Pyne S (2006) The effect of hypoxia on lipid phosphate receptor and sphingosine kinase expression and mitogen-activated protein kinase signaling in human pulmonary smooth muscle cells. Prostaglandins Other Lipid Mediat 79(3\u20134):278\u2013286","journal-title":"Prostaglandins Other Lipid Mediat"},{"issue":"6","key":"5056_CR48","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1074\/jbc.M708241200","volume":"283","author":"V Anelli","year":"2008","unstructured":"Anelli V, Gault CR, Cheng AB, Obeid LM (2008) Sphingosine kinase 1 is up-regulated during hypoxia in U87MG glioma cells. Role of hypoxia-inducible factors 1 and 2. J Biol Chem 283(6):3365\u20133375","journal-title":"J Biol Chem"},{"issue":"4","key":"5056_CR49","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.bbrc.2008.01.132","volume":"368","author":"S Schwalm","year":"2008","unstructured":"Schwalm S, Doll F, Romer I, Bubnova S, Pfeilschifter J, Huwiler A (2008) Sphingosine kinase-1 is a hypoxia-regulated gene that stimulates migration of human endothelial cells. Biochem Biophys Res Commun 368(4):1020\u20131025","journal-title":"Biochem Biophys Res Commun"},{"issue":"16","key":"5056_CR50","doi-asserted-by":"publisher","first-page":"4211","DOI":"10.1158\/0008-5472.CAN-18-3803","volume":"79","author":"S Acharya","year":"2019","unstructured":"Acharya S, Yao J, Li P, Zhang C, Lowery FJ, Zhang Q, Guo H, Qu J, Yang F, Wistuba II et al (2019) Sphingosine kinase 1 signaling promotes metastasis of triple-negative breast cancer. Cancer Res 79(16):4211\u20134226","journal-title":"Cancer Res"},{"key":"5056_CR51","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/B978-0-12-394274-6.00007-8","volume":"117","author":"LA Heffernan-Stroud","year":"2013","unstructured":"Heffernan-Stroud LA, Obeid LM (2013) Sphingosine kinase 1 in cancer. Adv Cancer Res 117:201\u2013235","journal-title":"Adv Cancer Res"},{"issue":"2","key":"5056_CR52","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2174\/1874467211003020053","volume":"3","author":"O Cuvillier","year":"2010","unstructured":"Cuvillier O, Ader I, Bouquerel P, Brizuela L, Malavaud B, Mazerolles C, Rischmann P (2010) Activation of sphingosine kinase-1 in cancer: implications for therapeutic targeting. Curr Mol Pharmacol 3(2):53\u201365","journal-title":"Curr Mol Pharmacol"},{"issue":"6","key":"5056_CR53","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.biochi.2010.02.008","volume":"92","author":"AJ Snider","year":"2010","unstructured":"Snider AJ, Orr Gandy KA, Obeid LM (2010) Sphingosine kinase: role in regulation of bioactive sphingolipid mediators in inflammation. Biochimie 92(6):707\u2013715","journal-title":"Biochimie"},{"key":"5056_CR54","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.jss.2018.06.019","volume":"232","author":"K Yuza","year":"2018","unstructured":"Yuza K, Nakajima M, Nagahashi M, Tsuchida J, Hirose Y, Miura K, Tajima Y, Abe M, Sakimura K, Takabe K et al (2018) Different roles of sphingosine kinase 1 and 2 in pancreatic cancer progression. J Surg Res 232:186\u2013194","journal-title":"J Surg Res"},{"issue":"9","key":"5056_CR55","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/nrd4099","volume":"12","author":"GT Kunkel","year":"2013","unstructured":"Kunkel GT, Maceyka M, Milstien S, Spiegel S (2013) Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov 12(9):688\u2013702","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"5056_CR56","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.tips.2017.04.003","volume":"38","author":"NJ Pyne","year":"2017","unstructured":"Pyne NJ, Adams DR, Pyne S (2017) Sphingosine kinase 2 in autoimmune\/inflammatory disease and the development of sphingosine kinase 2 inhibitors. Trends Pharmacol Sci 38(7):581\u2013591","journal-title":"Trends Pharmacol Sci"},{"issue":"5","key":"5056_CR57","first-page":"433","volume":"33","author":"DD Song","year":"2018","unstructured":"Song DD, Zhou JH, Sheng R (2018) Regulation and function of sphingosine kinase 2 in diseases. Histol Histopathol 33(5):433\u2013445","journal-title":"Histol Histopathol"},{"issue":"8","key":"5056_CR58","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1515\/hsz-2018-0237","volume":"399","author":"G van Echten-Deckert","year":"2018","unstructured":"van Echten-Deckert G, Alam S (2018) Sphingolipid metabolism - an ambiguous regulator of autophagy in the brain. Biol Chem 399(8):837\u2013850","journal-title":"Biol Chem"},{"issue":"1","key":"5056_CR59","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1158\/1541-7786.MCR-18-0199","volume":"17","author":"N Jafari","year":"2019","unstructured":"Jafari N, Drury J, Morris AJ, Onono FO, Stevens PD, Gao T, Liu J, Wang C, Lee EY, Weiss HL et al (2019) De novo fatty acid synthesis-driven sphingolipid metabolism promotes metastatic potential of colorectal cancer. Mol Cancer Res 17(1):140\u2013152","journal-title":"Mol Cancer Res"},{"issue":"11","key":"5056_CR60","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1158\/1541-7786.MCR-11-0336","volume":"9","author":"P Gao","year":"2011","unstructured":"Gao P, Smith CD (2011) Ablation of sphingosine kinase-2 inhibits tumor cell proliferation and migration. Mol Cancer Res 9(11):1509\u20131519","journal-title":"Mol Cancer Res"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-05056-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-022-05056-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-05056-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T21:19:42Z","timestamp":1675286382000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-022-05056-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,3]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["5056"],"URL":"https:\/\/doi.org\/10.1007\/s00277-022-05056-7","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,3]]},"assertion":[{"value":"20 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the Declaration of Helsinki and the International Council on Harmonization. The Duke Institutional Review Board (IRB) approved the protocol. All patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors approved the manuscript and the submission.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Yubin Kang received research funding from InCyte Corporation and a consultancy fee from Takeda Oncology USA and Sanofi Genzyme Corp. Charles Smith is the CEO and President, and Lynn Maines is employed by Apogee Biotechnology Corporation. Vered Katz Ben-Yair and Terry Plasse are consultants to RedHill Biopharma Limited. All other authors declare no competing conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}